Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 72

1.

The role of Piccolo in cancer treatment: relationship with EGFR and related therapies, and a marker for new targeted therapies.

Frattini M, Molinari F, Epistolio S.

J Thorac Dis. 2017 Nov;9(11):4240-4243. doi: 10.21037/jtd.2017.10.38. No abstract available.

2.

Individualized therapies in colorectal cancer: KRAS as a marker for response to EGFR-targeted therapy.

Chang DZ, Kumar V, Ma Y, Li K, Kopetz S.

J Hematol Oncol. 2009 Apr 22;2:18. doi: 10.1186/1756-8722-2-18. Review.

3.

Non-small cell lung cancer (NSCLC), EGFR downstream pathway activation and TKI targeted therapies sensitivity: Effect of the plasma membrane-associated NEU3.

Forcella M, Oldani M, Epistolio S, Freguia S, Monti E, Fusi P, Frattini M.

PLoS One. 2017 Oct 31;12(10):e0187289. doi: 10.1371/journal.pone.0187289. eCollection 2017.

4.

Role of epidermal growth factor receptor in lung cancer and targeted therapies.

Liu TC, Jin X, Wang Y, Wang K.

Am J Cancer Res. 2017 Feb 1;7(2):187-202. eCollection 2017. Review.

5.

Mechanisms of tumor resistance to EGFR-targeted therapies.

Hopper-Borge EA, Nasto RE, Ratushny V, Weiner LM, Golemis EA, Astsaturov I.

Expert Opin Ther Targets. 2009 Mar;13(3):339-62. doi: 10.1517/14712590902735795 . Review.

6.

Phase II trial of erlotinib and docetaxel in advanced and refractory hepatocellular and biliary cancers: Hoosier Oncology Group GI06-101.

Chiorean EG, Ramasubbaiah R, Yu M, Picus J, Bufill JA, Tong Y, Coleman N, Johnston EL, Currie C, Loehrer PJ.

Oncologist. 2012;17(1):13. doi: 10.1634/theoncologist.2011-0253. Epub 2011 Dec 30.

7.

EGFR targeted therapies and radiation: Optimizing efficacy by appropriate drug scheduling and patient selection.

Cuneo KC, Nyati MK, Ray D, Lawrence TS.

Pharmacol Ther. 2015 Oct;154:67-77. doi: 10.1016/j.pharmthera.2015.07.002. Epub 2015 Jul 21. Review.

8.

Targeted three-dimensional immunohistochemistry reveals localization of presynaptic proteins Bassoon and Piccolo in the rat calyx of Held before and after the onset of hearing.

Dondzillo A, Sätzler K, Horstmann H, Altrock WD, Gundelfinger ED, Kuner T.

J Comp Neurol. 2010 Apr 1;518(7):1008-29. doi: 10.1002/cne.22260.

PMID:
20127803
9.

Emerging treatment for advanced lung cancer with EGFR mutation.

Inal C, Yilmaz E, Piperdi B, Perez-Soler R, Cheng H.

Expert Opin Emerg Drugs. 2015;20(4):597-612. doi: 10.1517/14728214.2015.1058778. Epub 2015 Jul 8. Review.

PMID:
26153235
10.

Epidermal Growth Factor Receptor Inhibition in the Management of Squamous Cell Carcinoma of the Lung.

Goss GD, Spaans JN.

Oncologist. 2016 Feb;21(2):205-13. doi: 10.1634/theoncologist.2015-0209. Epub 2016 Jan 14. Review.

11.

Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial.

Seymour MT, Brown SR, Middleton G, Maughan T, Richman S, Gwyther S, Lowe C, Seligmann JF, Wadsley J, Maisey N, Chau I, Hill M, Dawson L, Falk S, O'Callaghan A, Benstead K, Chambers P, Oliver A, Marshall H, Napp V, Quirke P.

Lancet Oncol. 2013 Jul;14(8):749-59. doi: 10.1016/S1470-2045(13)70163-3. Epub 2013 May 29.

12.

A view on EGFR-targeted therapies from the oncogene-addiction perspective.

Perez R, Crombet T, de Leon J, Moreno E.

Front Pharmacol. 2013 Apr 26;4:53. doi: 10.3389/fphar.2013.00053. eCollection 2013.

13.

Piccolo regulates the dynamic assembly of presynaptic F-actin.

Waites CL, Leal-Ortiz SA, Andlauer TF, Sigrist SJ, Garner CC.

J Neurosci. 2011 Oct 5;31(40):14250-63. doi: 10.1523/JNEUROSCI.1835-11.2011.

15.

Mechanisms of resistance to EGFR targeted therapies.

Hrustanovic G, Lee BJ, Bivona TG.

Cancer Biol Ther. 2013 Apr;14(4):304-14. doi: 10.4161/cbt.23627. Epub 2013 Jan 28. Review.

16.
17.

Gastrointestinal cancer: PICCOLO--changing the tune of anti-EGFR therapy.

Killock D.

Nat Rev Clin Oncol. 2016 Apr;13(4):202-3. doi: 10.1038/nrclinonc.2016.32. Epub 2016 Mar 1. No abstract available.

PMID:
26925961
18.

[Identification of Piccolo as a regulator of behavioral plasticity and dopamine transporter internalization].

Nitta A, Hibi Y, Miyamoto Y, Nabeshima T.

Nihon Arukoru Yakubutsu Igakkai Zasshi. 2010 Dec;45(6):525-9. Review. Japanese.

PMID:
21387608
19.

Piccolo Promotes Vesicle Replenishment at a Fast Central Auditory Synapse.

Butola T, Wichmann C, Moser T.

Front Synaptic Neurosci. 2017 Oct 25;9:14. doi: 10.3389/fnsyn.2017.00014. eCollection 2017.

20.

Piccolo knockdown-induced impairments of spatial learning and long-term potentiation in the hippocampal CA1 region.

Ibi D, Nitta A, Ishige K, Cen X, Ohtakara T, Nabeshima T, Ito Y.

Neurochem Int. 2010 Jan;56(1):77-83. doi: 10.1016/j.neuint.2009.09.004. Epub 2009 Sep 17.

PMID:
19766155

Supplemental Content

Support Center